Please try another search
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Johan Christenson | 63 | 2016 | Independent Director |
Geoffrey I. Shapiro | - | 2019 | Scientific & Clinical Advisory Board Member |
Karen E. Knudsen | - | - | Scientific & Clinical Advisory Board |
Gabriela Gruia | 67 | 2023 | Independent Director |
Marc Duey | 66 | 2022 | Independent Director |
Timothy A. Yap | 48 | - | Scientific & Clinical Advisory Board Member |
Rifat Pamukcu | 65 | 2016 | Independent Director |
Eric J. Brown | - | - | Member of Scientific Advisory Board |
Zvi Gregorio Fridlender | - | - | Scientific & Clinical Advisory Board Member |
Bernd Robert Seizinger | 67 | 2015 | Independent Director |
Michael J. Grissinger | 69 | 2022 | Independent Director |
Richard Peters | 60 | 2020 | Independent Chairperson of the Board |
John B. Henneman | 61 | 2019 | Independent Director |
Oren Gilad | 56 | 2011 | Co-Founder, CEO, President & Director |
Jean-Pierre Bizzari | 70 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review